Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jochen K. Lennerz"'
Autor:
Enrico Moiso, Alexander Farahani, Hetal D. Marble, Austin Hendricks, Samuel Mildrum, Stuart Levine, Jochen K. Lennerz, Salil Garg
Publikováno v:
Cancer Discov
Cancer is partly a developmental disease, with malignancies named based on cell or tissue of origin. However, a systematic atlas of tumor origins is lacking. Here we map the single-cell organogenesis of 56 developmental trajectories to the transcript
Autor:
Islam Baiev, Jochen K. Lennerz, Lesli A. Kiedrowski, Mohammed Usman Syed, Chendi Li, Rebecca S. Heist, Samuel J. Klempner, Dejan Juric, Aaron N. Hata, Mustafa Sakhi, Katerina A. Fella, Ryan B. Corcoran, Alexa G. Michel, Justin F. Gainor, Junbing Zhang, Liron Bar-Peled, Jessica J. Lin, Meagan B. Ryan, Noritaka Tanaka, Giulia Siravegna
Publikováno v:
Cancer Discovery. 11:1913-1922
Mutant-selective KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510 (sotorasib), have demonstrated efficacy in KRASG12C-mutant cancers, including non–small cell lung cancer (NSCLC). However, mechanisms underlying clinical acquired resista
Autor:
Noritaka, Tanaka, Jessica J, Lin, Chendi, Li, Meagan B, Ryan, Junbing, Zhang, Lesli A, Kiedrowski, Alexa G, Michel, Mohammed U, Syed, Katerina A, Fella, Mustafa, Sakhi, Islam, Baiev, Dejan, Juric, Justin F, Gainor, Samuel J, Klempner, Jochen K, Lennerz, Giulia, Siravegna, Liron, Bar-Peled, Aaron N, Hata, Rebecca S, Heist, Ryan B, Corcoran
Publikováno v:
Cancer discovery. 11(8)
Mutant-selective KRAS
Autor:
Alice T. Shaw, Jochen K. Lennerz, Mari Mino-Kenudson, Hideko Isozaki, Subba R. Digumarthy, Inga T. Lennes, Rebecca J. Nagy, Corinne Clifford, Aaron N. Hata, Jessica J. Lin, Lecia V. Sequist, Mandeep Banwait, Amanda K. Riley, Dora Dias-Santagata, Justin F. Gainor, Zofia Piotrowska, Sai-Hong Ignatius Ou, Varuna Nangia, Viola W. Zhu, Rebecca S. Heist, Richard B. Lanman, Nicolas Marcoux, Wenjia Su, A. John Iafrate, Satoshi Yoda, Erica Evans, Beni B. Wolf
Publikováno v:
Cancer Discovery. 8:1529-1539
We present a cohort of 41 patients with osimertinib resistance biopsies, including 2 with an acquired CCDC6–RET fusion. Although RET fusions have been identified in resistant EGFR-mutant non–small cell lung cancer (NSCLC), their role in acquired
Autor:
Dora Dias-Santagata, Manrose Singh, Subba R. Digumarthy, Justin F. Gainor, Leila Dardaei, Rebecca S. Heist, Colleen L. Channick, Elizabeth L. Lockerman, Ryohei Katayama, Long P. Le, Ignaty Leshchiner, Ibiayi Dagogo-Jack, Alice T. Shaw, Lecia V. Sequist, Tiffany Huynh, Emily Chin, Ashok Muniappan, Mari Mino-Kenudson, Richard H. DiCecca, Jennifer A. Logan, Jochen K. Lennerz, Shirish M. Gadgeel, Gad Getz, Katherine Schultz, Luc Friboulet, A. John Iafrate, Jeffrey A. Engelman, Lauren L. Ritterhouse, Colleen Keyes, Dana Lee, Cyril H. Benes, Satoshi Yoda, Melissa Parks
Publikováno v:
Cancer Discovery. 6:1118-1133
Advanced, anaplastic lymphoma kinase (ALK)–positive lung cancer is currently treated with the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK inhibitors (e.g., ceritinib and alectinib) upon progression. Seco
Autor:
Islam Baiev, Raul N. Uppot, Leah Y. Liu, Giulia Siravegna, Isobel J Fetter, Stephanie Reyes, Dejan Juric, Cristina R. Ferrone, Emily E. Van Seventer, David T. Ting, Sachie Otsuki, Ipsita Dey-Guha, Jochen K. Lennerz, William C. Hahn, Lei Shi, Krushna C. Patra, Ignaty Leschiner, Gad Getz, Heather A. Shahzade, Cyril H. Benes, Phuong Vu, Robin Kate Kelley, Liudmila Elagina, Vikram Deshpande, Hiroshi Hirai, James J. Harding, Alberto Bardelli, Ferran Fece de la Cruz, Andrew X. Zhu, A. John Iafrate, Raymond W.S. Ng, Nabeel Bardeesy, Takeshi Sagara, Kenneth K. Tanabe, Rona Yaeger, Supriya K. Saha, Srivatsan Raghavan, Brandon Nadres, Janet E. Murphy, Ryan B. Corcoran, Ronald S. Arellano, Lipika Goyal
Publikováno v:
Cancer Discov
Cancer discovery, vol 9, iss 8
Cancer discovery, vol 9, iss 8
ATP-competitive fibroblast growth factor receptor (FGFR) kinase inhibitors, including BGJ398 and Debio 1347, show antitumor activity in patients with intrahepatic cholangiocarcinoma (ICC) harboring activating FGFR2 gene fusions. Unfortunately, acquir
Autor:
Zofia, Piotrowska, Hideko, Isozaki, Jochen K, Lennerz, Justin F, Gainor, Inga T, Lennes, Viola W, Zhu, Nicolas, Marcoux, Mandeep K, Banwait, Subba R, Digumarthy, Wenjia, Su, Satoshi, Yoda, Amanda K, Riley, Varuna, Nangia, Jessica J, Lin, Rebecca J, Nagy, Richard B, Lanman, Dora, Dias-Santagata, Mari, Mino-Kenudson, A John, Iafrate, Rebecca S, Heist, Alice T, Shaw, Erica K, Evans, Corinne, Clifford, Sai-Hong I, Ou, Beni, Wolf, Aaron N, Hata, Lecia V, Sequist
Publikováno v:
Cancer discovery. 8(12)
We present a cohort of 41 patients with osimertinib resistance biopsies, including two with an acquired CCDC6-RET fusion. While RET fusions have been identified in resistant EGFR-mutant NSCLC, their role in acquired resistance to EGFR inhibitors is n
Autor:
Alice T. Shaw, Luc Friboulet, Daria Timonina, Benjamin J. Burke, Krystina E. Kattermann, Justin F. Gainor, Jeffrey A. Engelman, Amanda K. Riley, A. John Iafrate, Jochen K. Lennerz, Adam Langenbucher, Sergei Timofeevski, Aaron N. Hata, Leila Dardaei, Cyril H. Benes, Lorin A. Ferris, Jessica J. Lin, Kylie Prutisto-Chang, Ted William Johnson, Harper Hubbeling, Rebecca S. Heist, Ibiayi Dagogo-Jack, Mari Mino-Kenudson, Satoshi Yoda, Michael S. Lawrence
Publikováno v:
Cancer Discovery
The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors. The third-generation ALK inhibitor lorlatinib has demonstrated clinical activity in patients who failed pr
Autor:
Gad Getz, Sabrina Baltschukat, Ignaty Leshchiner, Dejan Juric, Louise Barys, Andrew X. Zhu, Vikram Deshpande, Ralph Tiedt, Phuong Vu, James R. Stone, Jiaoyuan Elisabeth Sun, Joseph M. Gurski, Benedetta Mussolin, Lipika Goyal, Jochen K. Lennerz, Nabeel Bardeesy, Emily E. Van Seventer, Christelle Stamm, Stephanie Reyes, Avinash Kambadakone, Leah Y. Liu, L. Henderson, Alberto Bardelli, A. John Iafrate, David P. Ryan, Diana Graus Porta, Leanne G. Ahronian, Giulia Siravegna, Supriya K. Saha, Pascal Furet, Ryan B. Corcoran, Barbara Schacher-Engstler
Publikováno v:
Cancer discovery. 7(3)
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The FGFR inhibitor BGJ398 displayed encouraging efficacy in patients with
Autor:
Eunice L. Kwak, Leanne G. Ahronian, Giulia Siravegna, Benedetta Mussolin, Darrell R. Borger, Jason T. Godfrey, Nicholas A. Jessop, Jeffrey W. Clark, Lawrence S. Blaszkowsky, David P. Ryan, Jochen K. Lennerz, A. John Iafrate, Alberto Bardelli, Theodore S. Hong, Ryan B. Corcoran
Publikováno v:
Cancer discovery. 5(12)
MET inhibition is effective in some patients with MET-amplified esophagogastric cancer (EGC), but understanding acquired and de novo resistance mechanisms will be critical to improving therapy. We identified KRAS mutation as a novel cause of acquired